Oral rivaroxaban (Xarelto) noninferior to warfarin for PE (RCT)
www.pulmccm.org
(image: InPharm) Rivaroxaban (Xarelto) was noninferior to standard treatment (heparin and warfarin) in preventing recurrent VTE in patients with acute pulmonary embolism (PE), in the large EINSTEIN-PE randomized trial published in the April 5 New England Journal of Medicine
Oral rivaroxaban (Xarelto) noninferior to warfarin for PE (RCT)
Oral rivaroxaban (Xarelto) noninferior to…
Oral rivaroxaban (Xarelto) noninferior to warfarin for PE (RCT)
(image: InPharm) Rivaroxaban (Xarelto) was noninferior to standard treatment (heparin and warfarin) in preventing recurrent VTE in patients with acute pulmonary embolism (PE), in the large EINSTEIN-PE randomized trial published in the April 5 New England Journal of Medicine